Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$22.03 -1.4%	$17.84	$9.57 ▼ $27.34	$3.05B	1	2.48 million shs	2.39 million shs
CRNX Crinetics Pharmaceuticals	$30.99 +1.1%	$30.04	$24.10 ▼ $62.53	$2.92B	0.28	1.03 million shs	1.14 million shs
DAWN Day One Biopharmaceuticals	$7.51 -1.1%	$6.75	$5.64 ▼ $16.76	$769.26M	-1.25	2.07 million shs	893,899 shs
VKTX Viking Therapeutics	$27.05 -1.9%	$31.24	$18.92 ▼ $81.73	$3.04B	0.73	9.77 million shs	3.79 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	+3.28%	+38.29%	+34.33%	-7.55%
CRNX Crinetics Pharmaceuticals	0.00%	+0.23%	+11.31%	-2.79%	-41.59%
DAWN Day One Biopharmaceuticals	0.00%	+4.31%	+12.93%	+7.13%	-45.74%
VKTX Viking Therapeutics	0.00%	+4.04%	-17.23%	+3.56%	-57.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership
ARWR Arrowhead Pharmaceuticals	3.672 of 5 stars	3.5	1.0	3.4	3.0	2.5
CRNX Crinetics Pharmaceuticals	3.7017 of 5 stars	3.4	0.0	3.7	4.2	2.5
DAWN Day One Biopharmaceuticals	2.4264 of 5 stars	3.6	2.0	0.0	3.0	2.5
VKTX Viking Therapeutics	3.9732 of 5 stars	3.5	1.0	4.7	3.4	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	3.00	Buy	$43.14	95.84% Upside
CRNX Crinetics Pharmaceuticals	2.78	Moderate Buy	$68.86	122.19% Upside
DAWN Day One Biopharmaceuticals	3.13	Buy	$25.29	236.69% Upside
VKTX Viking Therapeutics	3.00	Buy	$86.92	221.34% Upside

Current Analyst Ratings Breakdown

Latest DAWN, ARWR, VKTX, and CRNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
8/18/2025	DAWN Day One Biopharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$25.00
8/11/2025	ARWR Arrowhead Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/11/2025	CRNX Crinetics Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$90.00 ➝ $86.00
8/8/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$40.00 ➝ $38.00
8/6/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $16.00
8/6/2025	DAWN Day One Biopharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $25.00
7/28/2025	ARWR Arrowhead Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/24/2025	VKTX Viking Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$125.00 ➝ $122.00
7/24/2025	VKTX Viking Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$31.00 ➝ $38.00

(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	857.99	N/A	N/A	$1.54 per share	14.31
CRNX Crinetics Pharmaceuticals	$1.04M	2,806.38	N/A	N/A	$14.29 per share	2.17
DAWN Day One Biopharmaceuticals	$131.16M	5.86	N/A	N/A	$4.99 per share	1.51
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.28	N/A	N/A	N/A	N/A	-40.91%	-11.62%	N/A
CRNX Crinetics Pharmaceuticals	-$298.41M	-$4.11	N/A	N/A	N/A	N/A	-32.28%	-29.45%	11/11/2025 (Estimated)
DAWN Day One Biopharmaceuticals	-$95.50M	-$0.95	N/A	N/A	N/A	-50.63%	-19.01%	-16.99%	10/29/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.53	N/A	N/A	N/A	N/A	-19.98%	-19.38%	10/22/2025 (Estimated)

Latest DAWN, ARWR, VKTX, and CRNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	-$1.26	-$0.32	-$1.26	$29.01 million	$27.77 million
8/7/2025	Q2 2025	CRNX Crinetics Pharmaceuticals	-$1.13	-$1.23	-$0.10	-$1.23	$0.52 million	$1.03 million
8/5/2025	Q2 2025	DAWN Day One Biopharmaceuticals	-$0.35	-$0.29	+$0.06	-$0.29	$35.55 million	$33.91 million
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	-$0.58	-$0.14	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.39	4.87	4.87
CRNX Crinetics Pharmaceuticals	N/A	17.80	17.80
DAWN Day One Biopharmaceuticals	N/A	9.65	9.53
VKTX Viking Therapeutics	N/A	25.86	25.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
CRNX Crinetics Pharmaceuticals	98.51%
DAWN Day One Biopharmaceuticals	87.95%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
CRNX Crinetics Pharmaceuticals	6.00%
DAWN Day One Biopharmaceuticals	6.20%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.26 million	132.31 million	Optionable
CRNX Crinetics Pharmaceuticals	210	94.18 million	88.53 million	Optionable
DAWN Day One Biopharmaceuticals	60	102.43 million	96.08 million	Optionable
VKTX Viking Therapeutics	20	112.44 million	107.84 million	Optionable

DAWN, ARWR, VKTX, and CRNX Headlines

Recent News About These Companies

FORA Capital LLC Has $268,000 Stock Holdings in Viking Therapeutics, Inc. $VKTX

September 1 at 4:43 AM | marketbeat.com

Invesco Ltd. Sells 787,865 Shares of Viking Therapeutics, Inc. $VKTX

September 1 at 3:31 AM | marketbeat.com

Rafferty Asset Management LLC Sells 87,394 Shares of Viking Therapeutics, Inc. $VKTX

August 31 at 5:22 AM | marketbeat.com

AlphaQuest LLC Acquires 9,815 Shares of Viking Therapeutics, Inc. $VKTX

August 31 at 4:26 AM | marketbeat.com

Raymond James Financial Inc. Buys 28,922 Shares of Viking Therapeutics, Inc. $VKTX

August 31 at 3:37 AM | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights

August 29 at 6:46 PM | zacks.com

Viking Therapeutics to Participate at Upcoming Investor Conferences

August 28, 2025 | prnewswire.com

Affinity Asset Advisors LLC Acquires Shares of 25,000 Viking Therapeutics, Inc. $VKTX

August 28, 2025 | marketbeat.com

Viking Therapeutics, Inc. $VKTX Shares Sold by Russell Investments Group Ltd.

August 28, 2025 | marketbeat.com

Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?

August 27, 2025 | zacks.com

Nuveen LLC Buys Shares of 384,379 Viking Therapeutics, Inc. $VKTX

August 26, 2025 | marketbeat.com

Short Report: Viking Therapeutics short interest at 5-year high after VK273 data

August 25, 2025 | msn.com

Viking Therapeutics, Inc. $VKTX Shares Sold by Charles Schwab Investment Management Inc.

August 25, 2025 | marketbeat.com

2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts

August 24, 2025 | fool.com

Is Viking Therapeutics stock a bargain after this week’s sell-off?

August 23, 2025 | msn.com

Analysts Set Viking Therapeutics, Inc. (NASDAQ:VKTX) Price Target at $86.92

August 23, 2025 | americanbankingnews.com

Viking Therapeutics (VKTX) Down 23.4% Since Last Earnings Report: Can It Rebound?

August 22, 2025 | msn.com

Viking Therapeutics (VKTX) Reports Increased Net Losses For Second Quarter

August 22, 2025 | finance.yahoo.com

Here's Why Shares in Viking Therapeutics Crashed This Week

August 22, 2025 | msn.com

Viking Therapeutics (VKTX) Rebounds on Bargain-Hunting. Are You Missing Out?

August 21, 2025 | insidermonkey.com

A Closer Look at Viking Therapeutics's Options Market Dynamics

August 21, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DAWN, ARWR, VKTX, and CRNX Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$22.03 -0.31 (-1.39%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$22.58 +0.56 (+2.52%)

As of 08/29/2025 07:59 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Crinetics Pharmaceuticals NASDAQ:CRNX

$30.99 +0.34 (+1.11%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$31.12 +0.13 (+0.42%)

As of 08/29/2025 06:37 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Day One Biopharmaceuticals NASDAQ:DAWN

$7.51 -0.08 (-1.05%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$7.50 0.00 (-0.07%)

As of 08/29/2025 04:20 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Viking Therapeutics NASDAQ:VKTX

$27.05 -0.53 (-1.92%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$27.14 +0.09 (+0.31%)

As of 08/29/2025 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time